RxDoctor Payments Data

Kenneth Baran, MD

Interventional Cardiology · Saint Paul, MNNPI 1962485797

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (44.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Medtronic at 38.2% of the total.

$16,327in general payments, 2019–2025

Across 67 payments — averaging $243.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Boston Scientific$3K
  • Integer Holdings Corporation$3K
  • Abbott$2K
  • Heraeus Medical Components, LLC$1K
  • Shockwave Medical, Inc$412
  • plus $729 from 7 others
$2,095in research payments, 2019–2025

Across 2 payments — averaging $1047.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$2K

What the payments were for

  • Consulting fees$6,42539%
  • Travel & lodging$7,33045%
  • Food & beverage$2,57216%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,327 in reported general payments places this provider in the 70th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$69,878
Medicare patients
165
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor47$44,930
EntrestoSacubitril/Valsartan11$21,146
EliquisApixaban24$16,999
Repatha SureclickEvolocumab15$13,487
XareltoRivaroxaban11$8,720
ClopidogrelClopidogrel Bisulfate109$1,299
Atorvastatin Calcium69$1,174
Metoprolol Succinate45$952
Rosuvastatin Calcium29$465
Amlodipine Besylate23$234
Metoprolol Tartrate23$168
Lisinopril12$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$16,99924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 84 interventional cardiology providers in Minnesota.

Other interventional cardiology in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →